Debapriya Basu

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 5 papers. Top paper: “A dual apolipoprotein C-II mimetic–apolipoprotein C-III antagonist peptide lowers plasma triglycerides”.

A dual apolipoprotein C-II mimetic–apolipoprotein C-III antagonist peptide lowers plasma triglycerides

Science Translational Medicine(2020)10.1126/scitranslmed.aaw7905

N/A

0DataRank · unranked

68 citations

Larry Lo, Denis Sviridov, Mohsen Pourmousa, Milton Pryor, Soumitra S. Ghosh +16 more

Hypertriglyceridemia and Atherosclerosis: Using Human Research to Guide Mechanistic Studies in Animal Models

Frontiers in Endocrinology(2020)10.3389/fendo.2020.00504

N/A

0DataRank · unranked

48 citations

Karin Bornfeldt, Debapriya Basu

Atherosclerosis Regression and Cholesterol Efflux in Hypertriglyceridemic Mice

Circulation Research(2021)10.1161/circresaha.120.317458

N/A

0DataRank · unranked

30 citations

Debapriya Basu, Tomáš Vaisar, Britt Arets, Jenny E. Kanter, Lesley-Ann Huggins +8 more

CREBH normalizes dyslipidemia and halts atherosclerosis in diabetes by decreasing circulating remnant lipoproteins

Journal of Clinical Investigation(2021)10.1172/jci153285

N/A

0DataRank · unranked

24 citations

Debapriya Basu, Jenny E. Kanter, Farah Kramer, Vishal Kothari, Shelley Barnhart +9 more

Angiopoietin-like 3: An important protein in regulating lipoprotein levels

Best Practice & Research Clinical Endocrinology & Metabolism(2022)10.1016/j.beem.2022.101688

N/A

0DataRank · unranked

22 citations

Debapriya Basu, Ira J. Goldberg, Nathan O. Stitziel, Kendall H. Burks